Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Eporgen's Portfolio Company Genovax Sells GX301, its Clinical-Stage Therapeutic Vaccine for the Treatment of Various Types of Cancer, to Mediolanum Farmaceutici

MILAN and COLLERETTO GIACOSA, Italy, December 3, 2012 /PRNewswire/ --

Mediolanum Farmaceutici SpA, a privately owned company that leads the Mediolanum Farmaceutici Group of companies, and Genovax srl, a private company which belongs to the portfolio of Eporgen Venture and was originated from the University of Genoa , announced the acquisition by Mediolanum of the global rights to GX301, Genovax's therapeutic vaccine to treat various types of cancer.  The first clinical study with GX301 was successfully completed earlier this year in prostate and renal cancer patients. Further clinical studies are scheduled to be initiated in the next few months, and all future development and commercialization activities will be the responsibility of Mediolanum with the support of Genovax. Under the agreement, Genovax will receive upfront and milestone payments as well as royalties.  

The acquisition of Genovax's innovative therapeutic vaccine for the treatment of various type of cancer is part of a strategy that we initiated since the late '90s and is a testament to our commitment to Research and Development", said Dr Rinaldo Del Bono, founder and President of Mediolanum Farmaceutici. "The acquisition of GX301 expands the interests of Mediolanum to a new therapeutic area (oncology). We look forward to advancing the development of the product through to its worldwide registration and make it available to cancer patients as soon as possible" added Dr Del Bono.

Dr Domenico Criscuolo, President of Genovax commented: "The agreement with Mediolanum is a remarkable achievement, which confirms the vision of all researchers who trusted in the therapeutic potential of GX301. In only four years Genovax's team was able to consolidate with clinical results the original idea and to attract the interest of Mediolanum, which will lead the further development work. My personal thanks to all Genovax team members, for their dedication and support to GX301 project, and a special acknowledgement to the memory of Silvano Fumero, who shared my enthusiasm for this project, and was instrumental for the foundation of Genovax."

Genovax was founded in March 2008 in Ivrea by Prof. Francesco Indiveri, Prof. Gilberto Filaci, Dr Daniela Fenoglio, Dr Giuseppe Balbi and Dr Domenico Criscuolo, with the financial support of Eporgen Venture. The science behind Genovax's technology was originated at the Centre of Excellence for Biomedical Research (CEBR), which is based at the University of Genoa. Konstantinos Efthymiopoulos, President of Eporgen Venture said: "We are delighted by this event which is the first major transaction of a company in our portfolio. It validates the vision of Eporgen's founder, the late Dr Silvano Fumero, and vindicates the 70 private shareholders of Eporgen who also believed in it and are nurturing innovation, Italian science and scientists and hope that new therapies will eventually emerge through their financial support. We would like to congratulate the Genovax team for bringing GX301 thus far and to wish every success in the further development of the product, hoping that it will become a life saving therapy for cancer patients."  

Further notes for Editors:

About GX301

GX301 is a telomerase-based vaccine against cancer, which completed in February 2012 the first phase I study in prostate and renal cancer patients with very promising results. The study was conducted in Italy and showed that GX301 was very well tolerated and that induced vaccine-specific immune response in all patients. Disease stabilisation was observed in about one third of the patients and overall survival was longer than expected.  GX301 is composed by multiple peptides and adjuvants and is designed to induce potent immune responses that are specific for cancer cells through the activation of both CD4+ and CD8+ T lymphocytes. It is envisaged that GX301 may be useful also in other types of cancer and this will be explored in future clinical studies.

About Genovax

Genovax srl is a privately held company based in Colleretto Giacosa (Torino, Italy) and is focusing on the development of therapeutic vaccines against cancer, such as GX301, or chronic inflammatory diseases such as Systemic Lupus Erythematosus (SLE), where the lead product is GX101.

About Mediolanum Farmaceutici

Mediolanum was founded in 1972 by Dr Rinaldo Del Bono and its headquarters are located in Milan (Italy). It is a private pharmaceutical group that develops, manufactures, promotes and markets ethical pharmaceutical products (internally-developed, acquired or in-licensed) and herbal nutritionals. About 25 products are being commercialized by the Group, to treat cardiovascular, respiratory, inflammatory and dermatological disorders, infections, allergies, epilepsy, anemia and neuropathic pain. The Group currently employs around 570 people and its main commercial activities are concentrated in Italy and France, while sales in other countries are currently obtained through out-licensing and export activities.  

About Eporgen Venture

Eporgen Venture (EV) is an Italian company, entirely funded by private, non-institutional investors, which is dedicated to seed capital investments in the area of life sciences. EV started its operations in 2005 and is based in the Bioparco "Silvano Fumero" in Colleretto Giacosa (Torino, Italy), where it created a portfolio of 11 companies (7 companies developing products and 4 companies developing technologies). These start-up companies are legally independent entities, controlled by EV, and are built around intellectual property that is being developed up to a proof-of-concept stage. The operating model of EV offers the virtues of the "asset-centric" investment model, but also the operating efficiencies of a small, virtual biotech with a centrally managed portfolio, guided by seasoned pharma and biotech executives. Since the start of its operations, EV has experienced a remarkable growth, by doubling the size of its investor base and of its portfolio of companies. Over the next six months EV is expected to complete further transactions and raise capital to advance the development of its assets.

Contacts:
Konstantinos Efthymiopoulos
President, Eporgen Venture SpA
T: +39-0125-561000
konstantinos@eporgen.com


SOURCE Eporgen Venture SpA

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
Dell and Red Hat Inc. have announced the availability of co-engineered, enterprise-grade, private cloud solutions based on OpenStack, the Dell Red Hat Cloud Solution, powered by Red Hat Enterprise Linux OpenStack Platform. The companies also have extended their collaboration to enable...
Last week was a crazy week for information security. That's probably also the understatement of the year. With the public exposure of Heartbleed, everyone was talking about what to do and how to do it to help customers and the Internet, in general, deal with the ramifications of such a...
Jelastic on Tuesday announced support for multiple ISV software packages in Jelastic’s products for enterprises, hosting service providers and developers. This support is achieved using OpenShift by Red Hat’s pluggable Cartridge standard, allowing those developers to build application ...
Red Hat on Monday announced OpenShift Marketplace, a one-stop shop that will enable customers to find and try solutions for their cloud applications. The OpenShift Marketplace will bring the power of Red Hat's OpenShift Platform-as-a-Service (PaaS) partner ecosystem directly to OpenShi...
ActiveState on Monday announced that Bernard Golden has joined the company as Vice President of Strategy. Named in Wired.com as one of the ten most influential people in cloud computing, Bernard has extensive experience working with organizations to help them adopt and integrate cloud ...
IBM has identified mobile devices, cloud computing and four other trends that are looking to shape the federal information technology of the future, according to Jane Snowdon, director and chief innovation officer at IBM Federal. In an op-ed for Federal Times, Snowdon writes that mbil...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE